Consumers trust Web for drug info

Share this article:
Seventy-five percent of consumers consider the Internet their most trusted source for researching drug information, a new survey shows.

The analysis, conducted by Prospectiv, showed that only 15% of consumers chose broadcast media as their most trusted and reliable source of ailment and drug information. Just 10% said magazines were their preferred source.

The survey of 800 US consumers, conducted in June, also found that online consumers favor general health Web sites. Fifty-four percent of respondents preferred general health sites, compared to 37% who chose specific ailment-focused sites. Just 4% said they preferred pharmaceutical company sites.

Prospectiv's president and CEO Jere Doyle said the survey's results confirm what many marketers have predicted for years—a shift to the Internet by consumers searching for healthcare information. “I think you will see dollars shift to the Internet but a combination of TV, print and Internet can be a real winning strategy,” Doyle said. “We also recommend building a database by finding those patients out there that suffer from the ailment your drug treats, getting them to ask, and beginning a relationship with them.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...